Inactivation of the RB1 and PTPN14 tumor suppressors cooperatively enables the carcinogenic activity of the human papillomavirus E7 oncoprotein

This study demonstrates that the carcinogenic activity of high-risk HPV E7 relies on the cooperative inactivation of two distinct tumor suppressors, RB1 and PTPN14, as neither mutant alone could immortalize keratinocytes, but their combined deficiency restored this capability.

The Gist

The Big Picture: A Viral Hijacker's Two Keys

Imagine your body's cells are like a high-security factory. This factory has strict rules about when it can build new products (cell division) and when it must stop and pack up (cell differentiation).

To keep the factory safe, there are two main security guards:

1. Guard RB1: He stands at the main gate. If he is on duty, he stops the workers from starting new production lines. He is the "Brake."
2. Guard PTPN14: He stands in the breakroom. He makes sure the workers don't get too comfortable or lazy; he pushes them to finish their shifts and go home (differentiation). He is the "Manager of Order."

The Villain: The Human Papillomavirus (HPV) is a master thief. It has a special tool called the E7 protein. The goal of the virus is to take over the factory and make it run forever, producing endless copies of itself. This is the first step toward cancer.

The Discovery: One Tool, Two Jobs

For a long time, scientists knew that the high-risk version of this virus (the kind that causes cancer) used its E7 tool to knock out Guard RB1. They thought, "If we just stop the brake, the factory runs wild, and that's how cancer happens."

But this new paper says: "Not so fast! That's only half the story."

The researchers discovered that the E7 tool actually has two distinct jobs:

1. Job A: It grabs Guard RB1 and throws him out the door (inactivating the brake).
2. Job B: It grabs Guard PTPN14 and throws him out the door (inactivating the manager).

The "Aha!" Moment:
The team created "broken" versions of the virus tool.

• Tool Version 1: Could grab RB1 but couldn't touch PTPN14.
• Tool Version 2: Could grab PTPN14 but couldn't touch RB1.

When they used just one broken tool, the factory stayed safe. The cells stopped growing after a while. The virus failed.
BUT, when they used both broken tools together in the same cell, the factory went into total chaos. The cells started growing forever, just like they would with the full, dangerous virus.

The Analogy: It's like trying to steal a car. If you only cut the brake lines (RB1), the car might roll a bit, but the engine won't start. If you only hotwire the ignition (PTPN14), the car won't move. But if you cut the brakes AND hotwire the ignition at the same time, the car takes off. You need both actions to make the car (or the cell) run away.

High-Risk vs. Low-Risk Viruses: The Difference in Skill

The paper also explains why some viruses are dangerous (High-Risk, like HPV 16 & 18) and others are mostly harmless (Low-Risk, like HPV 6 & 11).

• The Low-Risk Thief: This thief is clumsy. He can grab the Manager (PTPN14) and kick him out, which stops the workers from finishing their shifts. But he is too weak to grab the main Security Guard (RB1). Because the Brake is still working, the factory can't run wild enough to become cancer.
• The High-Risk Thief: This thief is a pro. He is strong enough to grab both the Manager and the Security Guard. He kicks them both out. With no brakes and no manager, the factory runs out of control, leading to cancer.

The Surprising Twist: Teamwork Makes the Dream Work

The researchers did something clever. They took the clumsy Low-Risk thief (who can't kick out the Security Guard) and helped him out.

• They artificially removed the Security Guard (RB1) from the factory.
• Suddenly, the clumsy Low-Risk thief could take over the factory!

Even more surprisingly, they found that if they removed the Manager (PTPN14), the Low-Risk thief could also take over.

What this means: The "danger" of the virus isn't just about how strong it is. It's about how many security guards it can disable. If you take away one guard, even a weak virus becomes dangerous. If you take away both, even a weak virus becomes a cancer-causing monster.

Why This Matters for You

1. Two Targets for Medicine: Since the virus needs to disable both guards to cause cancer, doctors might be able to develop new drugs that specifically help the body keep both guards on duty. If we can stop the virus from kicking out PTPN14, maybe we can stop cancer even if the virus is still there.
2. Understanding Cancer Risk: This explains why some people get cancer from HPV and others don't. It's not just about the virus; it's about the state of the cell's security system. If a person has a genetic weakness in one of these guards, a "low-risk" virus might suddenly become dangerous for them.

Summary in One Sentence

High-risk HPV causes cancer not just by disabling the cell's "brakes" (RB1), but by also disabling the "manager" (PTPN14); you need to lose both security systems for the cell to go rogue and become cancerous.

Technical Summary

1. Problem Statement

High-risk Human Papillomaviruses (HPVs), such as HPV16 and HPV18, are the primary etiological agents for cervical and oropharyngeal cancers. Their oncoprotein E7 is essential for cellular immortalization and carcinogenesis. While it is well-established that high-risk E7 binds to and inactivates the retinoblastoma tumor suppressor (RB1), this activity alone is necessary but insufficient for full transformation. High-risk E7 proteins also bind to and degrade Protein Tyrosine Phosphatase Non-Receptor Type 14 (PTPN14), a tumor suppressor that inhibits the YAP1 oncoprotein.

The central questions addressed in this study are:

1. Are RB1 inactivation and PTPN14 inactivation distinct, independent activities of E7 that must cooperate to drive carcinogenesis?
2. Why can high-risk HPV E7 proteins immortalize keratinocytes while low-risk E7 proteins (e.g., HPV6, HPV11) cannot, despite sharing many cellular targets?
3. What is the mechanistic basis for the difference in transforming potential between high- and low-risk E7 proteins?

2. Methodology

The authors employed a combination of genetic complementation, CRISPR interference (CRISPRi), biochemical binding assays, and transcriptomic analysis using primary human foreskin keratinocytes (HFKs).

• Genetic Complementation: The researchers generated pairs of retroviral vectors to co-express two different E7 mutants in the same cell.
  • Mutants: They used mutants defective in RB1 binding (HPV18 E7 $\Delta$DLLC; HPV16 E7 $\Delta$DLYC) and mutants defective in PTPN14 binding (HPV18 E7 R84A L91A; HPV16 E7 R77S).
  • Assay: They measured the ability of these combinations to extend the lifespan of primary HFKs (a proxy for immortalization) compared to wild-type (WT) E7 or single mutants.
• CRISPRi Knockdown: To test if the loss of specific tumor suppressors could "rescue" the transforming ability of low-risk E7, they used CRISPRi (dCas9-KRAB-MeCP2) to specifically deplete RB1 or PTPN14 mRNA levels in HFKs expressing low-risk HPV6 E7.
• Biochemical Analysis:
  • Biolayer Interferometry (BLI): Used to measure the binding affinity ($K_D$) of purified full-length E7 proteins (HPV16, 18, 6, 11) to the C-terminal phosphatase domain of PTPN14.
  • Western Blotting & qRT-PCR: Used to assess protein stability (RB1, PTPN14) and gene expression changes (E2F targets like CCNE2, PCNA; differentiation markers like KRT1, KRT10).
• Transcriptomics (RNA-seq): Performed on HFKs expressing high-risk (HPV16) vs. low-risk (HPV6) E7 to compare global gene expression patterns, specifically focusing on E2F target genes and PTPN14 knockout signatures.

3. Key Contributions

• Genetic Proof of Dual Requirement: The study provides the first genetic evidence that RB1 inactivation and PTPN14 inactivation are separate, independent activities of E7 that must occur simultaneously to extend keratinocyte lifespan. Neither activity alone is sufficient.
• Mechanism of Risk Stratification: The paper redefines the distinction between high- and low-risk HPV E7 proteins. The primary differentiator is not the ability to bind PTPN14 (which both do), but the magnitude of RB1 degradation and subsequent E2F activation. High-risk E7 robustly degrades RB1 and activates E2F targets; low-risk E7 does not.
• Synergistic Regulation Model: The authors propose a model where E7-mediated carcinogenesis requires the synergistic activation of two pathways:
  1. E2F-dependent pathway: Driven by RB1 inactivation.
  2. YAP1-dependent pathway: Driven by PTPN14 degradation.
     Low-risk E7 can extend lifespan if either pathway is artificially activated (via knockdown of the respective tumor suppressor), suggesting that the "missing" activity in low-risk E7 can be compensated for by the loss of the other tumor suppressor.

4. Key Results

• Complementation of Mutants:
  • Single mutants of HPV18 or HPV16 E7 (defective in either RB1 or PTPN14 binding) failed to extend HFK lifespan significantly compared to WT E7.
  • Co-expression of the RB1-binding mutant and the PTPN14-binding mutant in the same cell fully restored the ability to extend lifespan, recapitulating the phenotype of WT high-risk E7. This confirmed that the two functions are separable and cooperative.
• High-Risk vs. Low-Risk E7 Comparison:
  • RB1: High-risk E7 (HPV16/18) significantly reduced RB1 protein levels and induced E2F target genes (CCNE2, PCNA). Low-risk E7 (HPV6/11) had minimal effect on RB1 levels and failed to robustly induce E2F targets.
  • PTPN14: Both high- and low-risk E7 proteins reduced PTPN14 protein levels and downregulated differentiation markers (KRT1, KRT10).
  • Binding Affinity: BLI assays showed that while all E7 proteins bind PTPN14, high-risk E7 (especially HPV18) binds with higher affinity ($K_D \approx 26.6$ nM) than low-risk E7 ($K_D \approx 189$ nM), but all are capable of inducing PTPN14 degradation.
• Rescue of Low-Risk E7:
  • RB1 Depletion: Knocking down RB1 in cells expressing low-risk HPV6 E7 allowed for long-term cell propagation, mimicking high-risk E7 transformation.
  • PTPN14 Depletion: Unexpectedly, knocking down PTPN14 in cells expressing low-risk HPV6 E7 also extended lifespan.
  • Synergy: In cells expressing high-risk E7, PTPN14 knockdown further increased the expression of cell cycle genes (specifically CCNE2) beyond the level seen with E7 alone, suggesting a synergistic effect between E2F and YAP1 pathways on specific gene promoters.

5. Significance

• Redefining Carcinogenesis: The findings challenge the long-held view that RB1 inactivation is the sole critical driver of HPV-mediated transformation. Instead, they establish that dual inactivation of RB1 and PTPN14 is the critical threshold for immortalization.
• Therapeutic Implications: The study suggests that targeting either the E7/RB1 axis or the E7/PTPN14/YAP1 axis could be therapeutically beneficial. Furthermore, it implies that individuals with germline mutations in PTPN14 (which predispose to basal cell and cervical cancers) may be more susceptible to HPV-induced carcinogenesis even with lower-risk viral strains.
• Mechanistic Insight: The paper elucidates how low-risk HPVs can be "converted" into transforming agents by the loss of a single tumor suppressor, highlighting the plasticity of cellular transformation pathways. It proposes that the cooperative regulation of cell cycle genes by E2F and YAP1 is the fundamental mechanism driving the oncogenic potential of high-risk HPV.

In conclusion, this paper demonstrates that the carcinogenic activity of high-risk HPV E7 relies on a "two-hit" mechanism involving the simultaneous inactivation of the RB1 and PTPN14 tumor suppressors, which converge to drive cell cycle progression and block differentiation through the synergistic activation of E2F and YAP1 transcriptional programs.